Klinikum der Ruhr-Universität Bochum, Klinik für Thorax- und Kardiovaskularchirurgie und Erich und Hanna Klessmann-Institut für Kardiovaskuläre Forschung und Entwicklung, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany.
Mühlenkreiskliniken, Krankenhaus Lübbecke-Rahden, Institut für Anästhesiologie, Intensiv- und Notfallmedizin, Medizin Campus OWL, Ruhr-Universität Bochum, Bochum, Germany.
Mol Genet Genomic Med. 2019 Aug;7(8):e841. doi: 10.1002/mgg3.841. Epub 2019 Jul 10.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy with a prevalence of about 1:200. It is characterized by left ventricular hypertrophy, diastolic dysfunction and interstitial fibrosis; HCM might lead to sudden cardiac death (SCD) especially in the young. Due to low autopsy frequencies of sudden unexplained deaths (SUD) the true prevalence of SCD and especially of HCM among SUD remains unclear. Even in cases of proven SCD genetic testing is not a routine procedure precluding appropriate risk stratification and counseling of relatives.
Here we report a case of SCD in a 19-year-old investigated by combined forensic and molecular autopsy.
During autopsy of the index-patient HCM was detected. As no other possible cause of death could be uncovered by forensic autopsy the event was classified as SCD. Molecular autopsy identified two (probably) pathogenic genetic variants in FHL1 and MYBPC3. The MYBPC3 variant had an incomplete penetrance. The FHL1 variant was a de novo mutation. We detected reduced FHL1 mRNA levels and no FHL1 protein in muscle samples suggesting nonsense-mediated mRNA decay and/or degradation of the truncated protein in the SCD victim revealing a plausible disease mechanism.
The identification of the genetic cause of the SCD contributed to the rational counseling of the relatives and risk assessment within the family. Furthermore our study revealed evidences for the pathomechanism of FHL1 mutations.
肥厚型心肌病(HCM)是一种遗传性心肌病,患病率约为 1:200。其特征为左心室肥厚、舒张功能障碍和间质纤维化;HCM 可能导致心脏性猝死(SCD),尤其是在年轻人中。由于不明原因的猝死(SUD)的尸检频率较低,因此 SCD 的真实患病率以及 SUD 中 HCM 的患病率仍不清楚。即使在已确诊的 SCD 病例中,基因检测也不是常规程序,从而无法进行适当的风险分层和对亲属进行咨询。
我们在此报告一例通过法医和分子尸检联合调查的 19 岁 SCD 病例。
在对指数患者进行尸检时发现了 HCM。由于法医尸检未能发现其他可能的死因,因此将该事件归类为 SCD。分子尸检在 FHL1 和 MYBPC3 中鉴定出两个(可能)致病性基因突变。MYBPC3 变异具有不完全外显率。FHL1 变异是新生突变。我们在肌肉样本中检测到 FHL1 mRNA 水平降低且无 FHL1 蛋白,这表明无义介导的 mRNA 衰变和/或截短蛋白在 SCD 受害者中的降解,揭示了一种合理的疾病机制。
确定 SCD 的遗传原因有助于对亲属进行合理的咨询和家庭内的风险评估。此外,我们的研究还揭示了 FHL1 突变的发病机制的证据。